- Medicare Rules: Promoting Competition? (November 15, 2022)
- In Axios, David Ault Examines Biden Administration Plans to Reduce Drug Costs (October 24, 2022)
- Deborah Gersh and Harvey Cotton Present Webinar on Dobbs Case Abortion Privacy Provisions
(September 28, 2022)
- In Healthcare Risk Management, Deborah Gersh Examines Hospital Emergency Department Legal Issues After SCOTUS Abortion Ruling (September 8, 2022)
- In Law360, Health Care Attorneys Analyze How Enactment of the Inflation Reduction Act Paves the Way for Drug Pricing Reforms (September 1, 2022)
- Congress Paves the Way for Drug Pricing Reforms with Passage of the Inflation Reduction Act of 2022
(August 12, 2022)
- In Law360, Health Care Attorneys Co-Author Article on Privacy Guidance Related to Reproductive Health
(August 2, 2022)
- In Bloomberg Law, David Peloquin Discusses Privacy Protections Related to Reproductive Research (July 19, 2022)
- In Law360, Health Care Attorneys Analyze HHS Medicare Drug Reimbursement (July 8, 2022)
- In Modern Healthcare, Margaux Hall Discusses FTC Investigation of Pharmacy Benefit Managers (June 16, 2022)
- In Technology Transfer Tactics Health Care Attorneys Analyze HHS Opinion Clarifying Anti-Kickback Rules for Physician Inventors (May 19, 2022)
- In Law360, Attorneys Examine CMS Changes Coming to Medicare Part D Market (May 18, 2022)
-
D.C. Federal District Court Rules in Favor of Sentara Hospitals in Medicare Bad Debt Payment Case
(April 1, 2022)
- In Modern Healthcare, Margaux Hall Examines CMS Proposal for Medicare Part D Drugs (March 11, 2022)
- DOJ Increases Focus on Clinical Trial Fraud
(February 1, 2022)
- On HIMSS-TV, Christine Moundas Analyzes Digital Health 2021 Highlights and 2022 Outlook
(January 5, 2022)
- In Law360, Attorneys Analyze DOJ Civil Cyber-Fraud Initiative Impact on Health Care Companies
(December 22, 2021)
- A New Year for Drug Pricing and Price Reporting? What’s Happening Now and What’s New for 2022
(December 14, 2021)
- HHS Reverses Course on LDTs: COVID-19 LDTs Again Require FDA Premarket Review
(December 3, 2021)
- CMS Finalizes Repeal of Medicare “Breakthrough” Device Coverage Rule, Pledges to Invite Further Industry Input (November, 24, 2021)
- DOJ Civil Cyber-Fraud Initiative May Impact Health Care and Life Sciences Companies
(November 10, 2021)
- Interim Final Rule Implements Controversial Surprise Billing Arbitration Provisions
(October 14, 2021)
- In Law360, Attorneys Analyze Takeaways from D.C. Circuit Medicare Advantage Overpayment Ruling (October 13, 2021)
-
In New York Magazine’s The Cut, Mark Barnes Discusses the Biden Administration’s COVID-19 Vaccine Mandate for Workers (October 1, 2021)
- Margaux Hall to Present at Managed Markets & Account Management Strategies Conference (November 9, 2021)
- Margaux Hall and Alison Fethke to Present at PLI Webcast on Drug Pricing Evolving Legal and Policy Landscape (September 20, 2021)
- In Barron’s and USA Today, Mark Barnes Examines Whether President Biden’s New Vaccine Mandate Can Withstand Legal Challenges (September 13, 2021)
- Proposed Rule on CY 2022 Physician Fee Schedule Addresses Telehealth (Especially Mental Health), Drug Pricing and Reimbursement, Provider Enrollment, Vaccines, and Physician-Owned Distributor Transparency (August 13, 2021)
- Updated: Developments in Drug Pricing and Price Reporting as the Congressional Recess Approaches (August 2021)
(August 11, 2021)
- Developments in Drug Pricing and Price Reporting as the Congressional Recess Approaches (August 2021)
(August 3, 2021)
- Podcast: Non-binding Guidance: COVID-19 Vaccine Mandate Litigation (July 29, 2021)
- In Law360, Health Care Attorneys Examine Compliance Considerations for Pharmaceutical Testing Programs (June 7, 2021)
- Margaux Hall and Alison Fethke to Present at PLI Webcast on Drug Pricing Evolving Legal and Policy Landscape (September 20, 2021)
- Mark Barnes Examines Subject-Sponsor Interactions in Report on Research Compliance (June 1, 2021)
- Health Care Attorneys Analyze the Future of Telehealth (May 11, 2021)
- Capital Clubhouse Named Finalist in DC Congresswoman Eleanor Holmes Norton’s Community Project Funding Initiative (April 28, 2021)
- In Bloomberg Law, Attorneys Analyze Potential Costs of Reshoring Pharmaceutical Manufacturing
(April 9, 2021)
- Event: Navigating Life Sciences M&A Under the Biden Administration | Drug Pricing & Antitrust Considerations (March 25, 2021)
- What the U.S. Federal Government Might Learn from States About Regulating Drug Pricing (March 24, 2021)
- Podcast: CMMI Program Delays and Suspensions—Recommended Next Steps (March 18, 2021)
- Law360 Profiles Tara Fisher on Guiding Novavax in Pursuit of COVID-19 Vaccine (March 11, 2021)
- In Law360, Health Care Attorneys Analyze Information Blocking Rule Opportunities for Clinical Research (March 9, 2021)
- Event: Outlook 2021 – Washington, D.C. Updates and Insights on Life Sciences and Health Care (February 25, 2021)
- In Law360, Margaux Hall Examines Drug Commercialization and Market Access Strategies in Light of Drug Pricing Regulatory Uncertainty Under the Biden Administration
(February 16, 2021)
- 2022 Medicare Advantage and Part D Final Rule Includes Update to Star Ratings System and Implementing Coverage and Transparency Measures (February 5, 2021)
-
Medicare Expands Coverage of “Breakthrough” Medical Devices and Codifies “Reasonable and Necessary” Standard
(January 21, 2021)
- Health Care Co-Chairs Address Key Issues Facing Health Payers in 2021
(January 8, 2021)
- In Law360, Tom Bulleit Analyzes 2021 Health Policies Under the Biden Administration (January 5, 2021)
- In Law360, Attorneys Evaluate 2021 IPO Market (January 5, 2021)
- The 2020 Election and Health Care (December 15, 2020)
- In Bloomberg Law, Tom Bulleit Discusses New “Stark” and Anti-Kickback Rules for Value-Based Arrangements (November 25, 2020)
- In Law360, Health Care Attorneys Examine State Drug Pricing Reforms (November 25, 2020)
Cookie Settings
